Joint Pain Forum – News you can use!
CombinatoRx Drops Arthritis Drug
CombinatoRx Inc. said Thursday it abandoned a potential drug to treat
rheumatoid arthritis after clinical trials showed it did not
significantly decrease inflammation.
The Cambridge, Mass., biotechnology company said in a statement that
while its CRx-150 compound significantly decreased pain in patients, it
had no effect on inflammation.
"The level of activity observed with
CRx-150 would not be competitive within the CombinatoRx product
portfolio or the (rheumatoid arthritis) marketplace," said Alexis
Borisy, CombinatoRx's president and chief executive, in a statement.
CombinatoRx's lead prospective treatment for the condition, CRx-102, has shown more promising results, he added.
Shares of CombinatoRx Inc. fell 10 cents to $6 in morning trading.
Map | CONTACT